Edwards Stays On Track For ‘Mid-Teens’ TAVR Growth In 2021
Edwards Lifesciences reported $1.2bn in sales in the first quarter of 2021, up 5% year-over-year and exceeding the projections the company offered three months ago.
Edwards Lifesciences reported $1.2bn in sales in the first quarter of 2021, up 5% year-over-year and exceeding the projections the company offered three months ago.